SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Benesh Kathryn | Director | 2026-06-25 | Grant/award | 645 | $145K |
| Bitsberger Timothy S. | Director | 2026-06-25 | Grant/award | 645 | $145K |
| Carey Charles P | Director | 2026-06-25 | Grant/award | 645 | $145K |
| Carey Charles P | Director | 2026-06-25 | Grant/award | 422 | $95K |
| Cook Elizabeth A | Director | 2026-06-25 | Grant/award | 645 | $145K |
| Durkin Bryan T | Director | 2026-06-25 | Grant/award | 645 | $145K |
| Ford Harold Eugene Jr. | Director | 2026-06-25 | Grant/award | 645 | $145K |
| Ford Harold Eugene Jr. | Director | 2026-06-25 | Grant/award | 422 | $95K |
| GEPSMAN MARTIN J | Director | 2026-06-25 | Grant/award | 645 | $145K |
| Hobert William W | Director | 2026-06-25 | Grant/award | 645 | $145K |
| Hobert William W | Director | 2026-06-25 | Grant/award | 422 | $95K |
| Kaye Daniel G | Director | 2026-06-25 | Grant/award | 645 | $145K |
| Lockett Phyllis M | Director | 2026-06-25 | Grant/award | 645 | $145K |
| Lucas Deborah J | Director | 2026-06-25 | Grant/award | 645 | $145K |
| Maloney Patrick W | Director | 2026-06-25 | Grant/award | 645 | $145K |
| Mulchrone Patrick J | Director | 2026-06-25 | Grant/award | 645 | $145K |
| SHEPARD WILLIAM R | Director | 2026-06-25 | Grant/award | 645 | $145K |
| SHEPARD WILLIAM R | Director | 2026-06-25 | Grant/award | 422 | $95K |
| SHEPARD WILLIAM R | Director | 2026-06-25 | Open-market buy | 14 | $3K |
| SHEPARD WILLIAM R | Director | 2026-06-25 | Open-market buy | 325 | $75K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Operational, technology, and regulatory risks all deteriorated this cycle, with no offsetting easing. The November 2025 CyrusOne cooling failure—a realized market halt—anchors a pattern of worsening across third-party infrastructure dependency, AI/cybersecurity exposure, new clearing business complexity, and pending Congressional action on digital assets. Fixed-cost structure limits the company's ability to absorb the newly disclosed volume risk from sustained market stability.
6 company-specific · 1 common-mode
New disclosure of November 2025 critical cooling failure at CyrusOne data center causing market halt. Demonstrates realized operational risk and dependency on third-party infrastructure.
If we experience system failures or capacity constraints, our ability to conduct our operations and execute our business strategy could be materially harmed, and we could be subject to significant…
Added disclosure of November 2025 CyrusOne data center cooling failure causing market halt—concrete operational disruption demonstrating realized supply chain risk.
We, as well as many of our customers, depend on third-party service providers for a number of services that are important. An interruption or cessation of an important supply or service by any third…
Added disclosure of pending Congressional legislation on digital asset trading/clearing and ongoing litigation over event-based contracts, creating new regulatory and litigation risks.
We operate in a heavily regulated environment that imposes significant costs and competitive burdens on our business, and our failure to maintain compliance with regulations, our status as a…
New disclosure of material revenue and earnings risk: sustained market stability could reduce trading volumes and revenues, with fixed costs limiting downside mitigation.
Our business is subject to the impact of financial markets volatility, which is caused by conditions that are beyond our control. Trading volume in our markets and products is largely driven by the…
New Treasury/repo clearing business launch introduces operational and risk management complexity in unfamiliar securities clearing domain, escalating counterparty and operational risk.
Our business exposes us to substantial credit risk of our clearing firms and other counterparties and, consequently, a decrease in their financial resources could adversely affect us. Our clearing…
New disclosure of generative AI fraud risk—fabricated content enabling fund transfers and data theft—represents escalated, specific threat not previously disclosed.
We could be harmed by misconduct or errors that are difficult to detect and deter. There continues to be highly publicized cases involving fraud or other misconduct or manipulative activity by…
New disclosure of material AI-related risks: product development failure, regulatory uncertainty, IP/data privacy/cybersecurity exposure, competitive disadvantage, reputational harm.
Our use of artificial intelligence in our business may be unsuccessful and may give rise to various risks, which could adversely affect our business, reputation or operating results. Our financial…
CME Group announced multiple senior executive appointments: Jack Tobin to Deputy CFO (November 2026) and then CFO (March 2027), Matthew Render to Chief Accounting Officer (November 2026), and John Marchese to General Counsel (September 2026). These are material C-suite appointments affecting the company's financial and legal leadership structure. While Tobin's appointment involves a transition from his prior role as Chief Accounting Officer, the principal disclosed action is his promotion to CFO and joining the Management Team, making this an appointment event.
View raw filing on EDGAR →CME Group disclosed its Q2 2026 financial results via press release dated July 22, 2026, reporting revenue of $1.7 billion, operating income of $1.1 billion, net income of $1.0 billion, and diluted EPS of $2.88. The filing explicitly states that Exhibit 99.1 is "a copy of a press release of CME Group Inc. dated July 22, 2026, reporting CME Group Inc.'s financial results for the quarter ended June 30, 2026," which is the classic structure of an earnings release disclosure under Item 2.02.
View raw filing on EDGAR →Lynne C. Fitzpatrick has been appointed as Chief Executive Officer of CME Group, effective on the later of March 1, 2027, or the 2026 10-K filing date, succeeding Terrence A. Duffy. Duffy will transition to Executive Chairman, and compensatory arrangements have been established for both executives as part of the planned succession.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of CME Group's 2026 Annual Meeting of Shareholders held on June 9, 2026 (reconvened from May 14 due to quorum issues). The filing details voting outcomes on five substantive proposals: elimination of Class B-1, B-2, and B-3 director election rights (Items 4–6); a certificate of incorporation amendment (Item 7); and election of Class B directors (Item 8). The disclosure includes vote tallies, percentages, and quorum determinations across multiple share classes, which is the core content of a shareholder vote results disclosure under Item 5.07.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of CME Group's 2026 Annual Meeting of Shareholders held on May 14, 2026, including voting outcomes on director elections (14 equity directors), auditor ratification (Ernst & Young LLP), and advisory compensation approval. The filing presents detailed vote tallies (FOR, AGAINST, ABSTAIN) for each proposal, which is the core content of shareholder vote result disclosures required under Item 5.07.
View raw filing on EDGAR →